newsfilter
← Latest News
Business Wire·

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

– Interim Data Support Advancing RLYB116 as a Differentiated Therapeutic and Enable Progression to Cohort 2 –